CervoMed Showcases Leadership in Advancing the Treatment and Care of Dementia with Lewy Bodies at the Alzheimer's Association International Conference (AAIC) 2026

New neflamapimod findings will be presented highlighting effects on dementia with Lewy bodies (DLB) progression, neurodegeneration biomarkers, basal forebrain atrophy, and proposed optimal dosing strategies. The announcement is informational with no efficacy/safety figures provided, implying limited near-term implications for pricing.

Analysis

New neflamapimod findings will be presented highlighting effects on dementia with Lewy bodies (DLB) progression, neurodegeneration biomarkers, basal forebrain atrophy, and proposed optimal dosing strategies. The announcement is informational with no efficacy/safety figures provided, implying limited near-term implications for pricing.